Weight-Loss Drugs Need Guiderails

Across the country, an increasing number of Americans now turn to weight-loss medications to treat obesity and related diseases. In 2026, 11% of Americans say that they are currently on these medications, more than three times higher than the rate in 2024. With decreasing prices, the introduction of new medications, and the approval of weight-loss drugs for additional health conditions, these medications are revolutionizing the healthcare sector in America. While these drugs have the potential to improve millions of lives, their rapid rise in popularity also needs stronger oversight to ensure they are used safely. 

This increase in the usage of medications such as like GLP-1s is brought forth by decades of struggles with obesity in the United States. Nearly two out of every five American adults have obesity, a condition that significantly increases the risk of heart disease, stroke, type 2 diabetes, certain cancers, and other chronic illnesses. Now, however, some progress is being made in this area, due to the effectiveness of newer weight-loss medications and greater awareness of obesity as a chronic disease. Namely, The overall obesity rate fell from its maximum of 39.9% in 2022 to 36.4% in 2023, with diagnoses of diabetes also stopping rising for the first time in over a decade.

Weight-loss drugs may be considered are a positive trend because they give patients another tool to manage serious health conditions. Obesity is not always a problem that can simply be solved by telling someone to “eat less and exercise more.” For some patients, medication can provide medical support when traditional approaches have not been effective. Making these drugs unnecessarily difficult to access could prevent patients who genuinely need treatment from receiving it.

However, easier access should not mean unrestricted access. The growing popularity of weight-loss drugs has also created a troubling market for compounded, or customized, versions of the medications that are much more difficult to regulate. According to a recent Gallup poll, 19 percent of current obesity medication users reported taking a compounded version. These copycat drugs are not FDA-approved, and the FDA has warned that they can carry risks and should only be used in certain situations.

Advertising also needs stronger limits. Weight-loss drugs should be presented as serious medications, not trendy shortcuts to achieving a certain body type. Ads that glamorize rapid weight loss can pressure healthy people to seek prescriptions for cosmetic reasons and reinforce unrealistic beauty standards. Companies should be required to clearly explain side effects, long-term commitments, and who the medication is actually intended for.

Those who advocate for reduced regulations claim that an increased access will provide treatment for more patients means more patients will be able to get access to the treatment, encourages competition that lowers prices, and gives patients an option to select the drug that suits them. They also argued that extensive regulations may slow innovation and pose unnecessary barriers to those suffering from obesity. While their concerns are valid, the safety of the patient should always come first. Access to the treatment should be regulated through the proper medications approved by the FDA.

Weight-loss drugs have the potential to improve millions of lives, but their popularity cannot replace medical responsibility. Doctors, regulators, and drug companies must ensure that these medications remain accessible to patients who need them while restricting unsafe compounded drugs and misleading advertisements. America should embrace medical progress, but it must put stronger guardrails in place before weight-loss drugs become just another product sold by hype.